10th Nov 2021 10:51
(Alliance News) - Freeline Therapeutics Holdings PLC, a portfolio holding of Syncona Ltd, on Wednesday reported a widened loss but noted encouraging data from its Fabry's disease trials.
Syncona is a London-based investment trust focussed on healthcare. Freeline is a Stevenage, Hertfordshire-based biotechnology company focused on liver directed gene therapies for bleeding disorders.
Freeline's net loss widened in the nine months to September 30 to USD105.7 million from USD58.2 million last year, as it ramped up research & development costs, which rose to USD70.8 million from USD55.3 million. General & administrative expenses doubled 37.2 million from USD14.9 million.
Freeline also said that the second patient dosed in Phase 1 & 2 trial for Fabry disease has generated "encouraging data". This is regarding the clinical trial of FLT190 for the treatment of Fabry disease, a rare inherited condition that affects enzymes that metabolise fat.
"The patient remains off enzyme replacement therapy more than 16 weeks post-dosing; first patient shows durable expression of the key enzyme (α-Gal A), which is absent or markedly deficient in patients, over two years with promising efficacy," it said.
Third patient in the trial for Fabry's disease will be dosed at the same dose level as the second patient with additional safety monitoring after a case of mild and transient myocarditis was observed.
"We are pleased that Freeline has been able to re-initiate clinical studies and are encouraged by the data generated by the second patient dosed in the Phase 1 & 2 Fabry's study. We are fully supportive of the safety protocols recommended by the data monitoring committee and look forward to seeing further progress from this study," said Chris Hollowood, who is the chief investment office of Syncona's investment arm and chair of Freeline.
Syncona shares were down 0.1% to 200.73 pence each in London on Wednesday morning.
By Greg Roxburgh; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Syncona